A Pilot Treatment Study of Insulin-Like Growth Factor-1 (IGF-1) in Autism Spectrum Disorder
Status:
Recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
The proposed project will pilot the use of IGF-1 as a novel treatment for core symptoms of
autism. We will use a double-blind, placebo-controlled crossover trial design in five
children with autism to evaluate the impact of IGF-1 treatment on autism-specific impairments
in socialization, language, and repetitive behaviors. We expect to provide evidence for the
safety and feasibility of IGF-1 in ameliorating social withdrawal in children with Autistic
Disorder. Further, we expect to demonstrate that IGF-1 is associated with improvement on
secondary outcomes of social impairment, language delay, and repetitive behavior, as well as
on functional outcomes of global severity.